scholarly journals AB0412 URINARY SOLUBLE VCAM-1 IS A USEFUL BIOMARKER OF DISEASE ACTIVITY AND TREATMENT RESPONSE IN LUPUS NEPHRITIS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1506.1-1507
Author(s):  
A. A. Gasparin ◽  
N. Pamplona Bueno de Andrade ◽  
V. Hax ◽  
P. Palominos ◽  
M. Siebert ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Disease Activity ◽  
Cell Adhesion Molecule ◽  
Urinary Biomarkers ◽  
Creatinine Ratio ◽  
Vascular Cell Adhesion ◽  
Systemic Lupus ◽  
Urine Protein ◽  
Research Support ◽  
Cell Adhesion Molecule 1

Background:The traditional lupus nephritis (LN) biomarkers are not sensitive nor specific enough for detecting ongoing disease activity and early relapse of nephritis and they do not reflect kidney damage nor have prognostic value1. Urinary biomarkers are directly excreted by the kidney and are easily obtained. They can also differentiate the renal activity of the disease from other organic manifestations more accurately than the serum biomarkers2. Vascular cell adhesion molecule-1 (VCAM-1) is involved in the progression of glomerular and tubulointerstitial injury in LN and its soluble form can be easily assessed in urine (uVCAM-1)3. Several studies correlated the uVCAM-1 levels with urine protein-creatinine ratio (UPC), with general disease activity and with active LN3.Objectives:To assess uVCAM-1 as a biomarker of disease activity and treatment response in LN.Methods:This prospective study enrolled patients with class III, IV or V LN diagnosed within the last three years and divided them in two groups: with and without active nephritis at the inclusion. The patients with active nephritis were included before they started a new immunosuppressive treatment. Active LN was defined as proteinuria (UPC≥0.5) plus active urinary sediment (hematuria, leukocyturia or cellular hematic/granular casts). At each visit, a urine sample was collected for uVCAM-1 evaluation and the nephritis status was accessed.Results:Median uVCAM-1 level was elevated in patients with active compared to inactive LN (p<0.001). The ROC curve of uVCAM-1 demonstrated an AUC of 0.84 and a cutoff of 47.2 ng/mgCr yielded a good sensitivity (74.2%) and specificity (74.2%) for the diagnosis of active LN. A significant correlation was found between uVCAM-1 level and renal activity scores and traditional biomarkers of LN (table 1). The level of uVCAM-1 dropped in patients with active LN who went into remission (p<0.001), increased in patients who went into activity (p=0.002) and did not change in patients who remained inactive (p=0.797) (figure 1). The level of uVCAM-1 peaked during the flare of LN (p<0.05) (figure 2).Table 1.Correlations between urinary soluble VCAM-1 and other LN biomarkers/disease scoresLN biomarkers/disease scoresVCAM-1SLEDAI-2k0.597***Renal SLEDAI0.569***Renal SLAM-R0.470***Renal SLICC0.620***Anti-dsDNA0.342**C3-0.344**C4-0.382**UPC0.654***Spearman’s correlation coefficients*pvalue <0.05; **pvalue <0.01; ***pvalue <0.001C, complement; LN, lupus nephritis; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; renal SLAM-R, The renal Systemic Lupus Activity Measure revised; renal SLICC, The Systemic Lupus International Collaborating Clinics renal activity/response exercise; UPC, urine protein-creatinine ratio.Conclusion:The uVCAM-1 is a reliable biomarker that reflects renal disease activity and is useful for monitoring individual patients with lupus nephritis over time.References:[1]Mok CC. Biomarkers for lupus nephritis: A critical appraisal. J Biomed Biotechnol. 2010;2010:638413.[2]Reyes-Thomas J, Blanco I, Putterman C. Urinary Biomarkers in Lupus Nephritis. Clin Rev Allergy Immunol. 2010;40:138–50.[3]Gasparin AA, Pamplona Bueno de Andrade N, Hax V, Tres GL, Veronese FV, Monticielo OA. Urinary biomarkers for lupus nephritis: the role of the vascular cell adhesion molecule-1. Lupus. 2019;28:265-272.Acknowledgments:We acknowledge the Research Incentive Fund (FIPE/HCPA) and the Research Support Fund of Brazilian Society of Rheumatology that supported this work.Disclosure of Interests:Andrese Aline Gasparin: None declared, Nicole Pamplona Bueno de Andrade: None declared, Vanessa Hax: None declared, Penelope Palominos Grant/research support from: This work was sponsored by the regional society of rheumatology (Sociedade de Reumatologia do Rio Grande do Sul)., Marina Siebert: None declared, Romulo Marx: None declared, Pedro Shaefer: None declared, Francisco Veríssimo Veronese: None declared, Odirlei Monticielo: None declared

scholarly journals Urinary Vascular Cell Adhesion Molecule, But Not Neutrophil Gelatinase-associated Lipocalin, Is Associated with Lupus Nephritis

2012 ◽  
Vol 39 (6) ◽  
pp. 1231-1237 ◽  
Author(s):  
ADNAN N. KIANI ◽  
TIANFU WU ◽  
HONG FANG ◽  
XIN J. ZHOU ◽  
CHUL W. AHN ◽  
...  
Keyword(s):  
Cell Adhesion ◽  
Lupus Nephritis ◽  
Disease Activity ◽  
Adhesion Molecule ◽  
Cell Adhesion Molecule ◽  
Vascular Cell Adhesion ◽  
Systemic Lupus ◽  
Vascular Cell ◽  
Neutrophil Gelatinase Associated Lipocalin ◽  
Neutrophil Gelatinase

Objective.Vascular cell adhesion molecule-1 (VCAM-1), an adhesion molecule, is involved in the progression of glomerular and tubulointerstitial injury. Neutrophil gelatinase-associated lipocalin (NGAL), a member of the lipocalin superfamily, has been shown to rise in both acute and chronic kidney damage. Both VCAM-1 and NGAL have been found at high levels in the urine of patients with active lupus nephritis. We investigated both as potential biomarkers for lupus nephritis.Methods.VCAM-1 and NGAL were measured by ELISA during 1 to 8 clinic visits in 107 patients with systemic lupus erythematosus (SLE; 91% women, 51% black, 36% white, 4% Asian, 4% Hispanic, and 5% others) for a total of 190 visits. Patients’ mean age was 41 years. We analyzed the relationship between these potential urine biomarkers and the urine protein/creatinine ratio (urine Pr/Cr), the Systemic Lupus International Collaborating Clinics (SLICC) renal activity score, SLE Disease Activity Index renal descriptors, and other clinical variables.Results.VCAM-1 levels were strongly associated with the physician’s global estimate of disease activity (p = 0.0002), the renal visual analog scale (p < 0.0001), the urine Pr/Cr (p < 0.0001), and SLICC renal activity score (p < 0.0001). VCAM-1 levels were also associated with a urine Pr/Cr ≥ 0.5 (p < 0.0001). NGAL was not associated with any measure of disease activity or with lupus serologies.Conclusion.Urine VCAM-1 had a strong association with measures of disease activity, including multiple renal activity descriptors. In contrast to previous SLE studies, NGAL failed to show any association with lupus nephritis.

Elevated Urinary and Blood Vascular Cell Adhesion Molecule-1 as Potential Biomarkers for Active Systemic Lupus Erythematosus: A Meta-analysis

2020 ◽  
Vol 26 (46) ◽  
pp. 5998-6006
Author(s):  
Yuan-Rui Xia ◽  
Yan-Mei Mao ◽  
Jun-Ping Wang ◽  
Qing-Ru Li ◽  
Yin-Guang Fan ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Cell Adhesion ◽  
Disease Activity ◽  
Adhesion Molecule ◽  
Lupus Erythematosus ◽  
Cell Adhesion Molecule ◽  
Vascular Cell Adhesion ◽  
Systemic Lupus ◽  
Vascular Cell ◽  
Cell Adhesion Molecule 1

Objective: Due to the inconsistent results of current studies on the association between urinary and blood vascular cell adhesion molecule-1 (VCAM-1) and systemic lupus erythematosus (SLE) disease activity, we conducted this study and analyzed its influencing factors. Methods: A literature search was conducted in PubMed, EMBASE, Web of Science, and Cochrane Library. Data were extracted from eligible studies to calculate standardized mean differences (SMD) with 95% confidence intervals (CI). Cochrane Q test and I2 statistics were used to examine heterogeneity. The sources of heterogeneity were assessed through sensitivity analysis and subgroup analysis. Publication bias was evaluated by funnel plots and Egger's test. Results: A total of 15 studies met the inclusion criteria, including 473 active SLE patients and 674 inactive SLE patients. The random effects model was used for data analysis. In both urine and blood samples, VCAM- 1 level in active SLE patients was significantly higher than those in inactive SLE patients (urine: SMD: 0.769; 95% CI: 0.260-1.278; blood: SMD=0.655, 95% CI: 0.084-1.226). No publication bias was found in this study. Conclusion: Compared with inactive SLE patients, patients with active SLE have higher levels of VCAM-1 in both urine and blood. VCAM-1 may be a potential indicator of SLE disease activity.

scholarly journals Urinary Soluble VCAM-1 is a Useful Biomarker of Disease Activity and Treatment Response in Lupus Nephritis

2020 ◽  
Author(s):  
Andrese Aline Gasparin ◽  
Nicole Pamplona Bueno de Andrade ◽  
Vanessa Hax ◽  
Penélope Esther Palominos ◽  
Marina Siebert ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Disease Activity ◽  
Treatment Response ◽  
Cell Adhesion Molecule ◽  
Good Sensitivity ◽  
Class Iii ◽  
Vascular Cell Adhesion ◽  
Tubulointerstitial Injury ◽  
Cell Adhesion Molecule 1 ◽  
Over Time

Abstract Background: Vascular cell adhesion molecule-1 (VCAM-1) is involved in the progression of glomerular and tubulointerstitial injury in lupus nephritis (LN) and can be easily assessed in urine. The aim of this study was to assess urinary soluble VCAM-1 (uVCAM-1) as a biomarker of disease activity and treatment response in LN.Methods: This prospective study enrolled patients with class III, IV or V LN diagnosed within the last three years and divided them in two groups: with and without active nephritis at the inclusion. At each visit, a urine sample was collected for uVCAM-1 evaluation and the nephritis status was assessed.Results: Median uVCAM-1 level was elevated in patients with active compared to inactive LN (P<0.001). The ROC curve of uVCAM-1 demonstrated an AUC of 0.84 and a cutoff of 47.2 ng/mgCr yielded a good sensitivity (74.2%) and specificity (74.2%) for the diagnosis of active LN. A significant correlation was found between uVCAM-1 level and renal activity scores and traditional biomarkers of LN. The level of uVCAM-1 dropped in patients with active LN who went into remission (P<0.001), increased in patients who went into activity (P=0.002) and did not change in patients who remained inactive (P=0.797). The level of uVCAM-1 peaked during the flare of LN (P<0.05).Conclusion: The uVCAM-1 is a reliable biomarker that reflects renal disease activity and is useful for monitoring individual patients with lupus nephritis over time.

scholarly journals Urinary soluble VCAM-1 is a useful biomarker of disease activity and treatment response in lupus nephritis

2020 ◽  
Vol 4 (1) ◽  
Author(s):  
Andrese Aline Gasparin ◽  
Nicole Pamplona Bueno de Andrade ◽  
Vanessa Hax ◽  
Penélope Esther Palominos ◽  
Marina Siebert ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Disease Activity ◽  
Treatment Response ◽  
Cell Adhesion Molecule ◽  
Good Sensitivity ◽  
Class Iii ◽  
Vascular Cell Adhesion ◽  
Tubulointerstitial Injury ◽  
Cell Adhesion Molecule 1 ◽  
Over Time

Abstract Introduction Vascular cell adhesion molecule-1 (VCAM-1) is involved in the progression of glomerular and tubulointerstitial injury in lupus nephritis (LN) and can be easily assessed in urine. The aim of this study was to assess urinary soluble VCAM-1 (uVCAM-1) as a biomarker of disease activity and treatment response in LN. Methods This prospective study enrolled 62 patients with class III, IV or V LN diagnosed within the last 3 years and divided them in two groups: with and without active nephritis at the inclusion, each group with 31 patients. At each visit, a urine sample was collected for uVCAM-1 evaluation and the nephritis status was assessed. Results Median uVCAM-1 level was elevated in patients with active compared to inactive LN (P < 0.001). The ROC curve of uVCAM-1 demonstrated an AUC of 0.84 and a cutoff of 47.2 ng/mgCr yielded a good sensitivity (74.2%) and specificity (74.2%) for the diagnosis of active LN. A significant correlation was found between uVCAM-1 level and renal activity scores and traditional biomarkers of LN. The level of uVCAM-1 dropped in patients with active LN who went into remission (P < 0.001), increased in patients who went into activity (P = 0.002) and did not change in patients who remained inactive (P = 0.797). The level of uVCAM-1 peaked during the flare of LN (P < 0.05). Conclusion The uVCAM-1 is a reliable biomarker that reflects renal disease activity and is useful for monitoring individual patients with lupus nephritis over time.

Urinary biomarkers for lupus nephritis: the role of the vascular cell adhesion molecule-1

Lupus ◽  
2019 ◽  
Vol 28 (3) ◽  
pp. 265-272 ◽  
Author(s):  
A A Gasparin ◽  
N Pamplona Bueno de Andrade ◽  
V Hax ◽  
G Leví Tres ◽  
F V Veronese ◽  
...  
Keyword(s):  
Cell Adhesion ◽  
Lupus Nephritis ◽  
Adhesion Molecule ◽  
Cell Adhesion Molecule ◽  
Urinary Biomarkers ◽  
Vascular Cell Adhesion ◽  
Vascular Cell ◽  
Vascular Cell Adhesion Molecule ◽  
Renal Histology ◽  
Cell Adhesion Molecule 1

Renal involvement is one of the main complications of systemic lupus erythematosus, causing a significant impact on patients' morbidity and mortality. Renal biopsy is still the gold standard of diagnosis, but it has many limitations. In this sense, several recent studies aim to identify biomarkers that not only predict disease activity and renal histology, but also lead to earlier treatment. In previous studies, the soluble vascular cell adhesion molecule-1 measured in urine showed a strong association with the presence of lupus nephritis, with clinical and histological activity indexes of the disease and with more severe renal lesions. This paper reviews the main urinary biomarkers of lupus nephritis that have been studied, with special emphasis on vascular cell adhesion molecule-1 results.

scholarly journals Urinary soluble VCAM-1 is a useful biomarker of disease activity and treatment response in lupus nephritis

2020 ◽  
Author(s):  
Andrese Aline Gasparin ◽  
Nicole Pamplona Bueno de Andrade ◽  
Vanessa Hax ◽  
Penélope Esther Palominos ◽  
Marina Siebert ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Disease Activity ◽  
Treatment Response ◽  
Cell Adhesion Molecule ◽  
Good Sensitivity ◽  
Class Iii ◽  
Vascular Cell Adhesion ◽  
Tubulointerstitial Injury ◽  
Cell Adhesion Molecule 1 ◽  
Over Time

Abstract Introduction: Vascular cell adhesion molecule-1 (VCAM-1) is involved in the progression of glomerular and tubulointerstitial injury in lupus nephritis (LN) and can be easily assessed in urine. The aim of this study was to assess urinary soluble VCAM-1 (uVCAM-1) as a biomarker of disease activity and treatment response in LN.Methods: This prospective study enrolled 62 patients with class III, IV or V LN diagnosed within the last three years and divided them in two groups: with and without active nephritis at the inclusion, each group with 31 patients. At each visit, a urine sample was collected for uVCAM-1 evaluation and the nephritis status was assessed.Results: Median uVCAM-1 level was elevated in patients with active compared to inactive LN (P<0.001). The ROC curve of uVCAM-1 demonstrated an AUC of 0.84 and a cutoff of 47.2 ng/mgCr yielded a good sensitivity (74.2%) and specificity (74.2%) for the diagnosis of active LN. A significant correlation was found between uVCAM-1 level and renal activity scores and traditional biomarkers of LN. The level of uVCAM-1 dropped in patients with active LN who went into remission (P<0.001), increased in patients who went into activity (P=0.002) and did not change in patients who remained inactive (P=0.797). The level of uVCAM-1 peaked during the flare of LN (P<0.05).Conclusion: The uVCAM-1 is a reliable biomarker that reflects renal disease activity and is useful for monitoring individual patients with lupus nephritis over time.

scholarly journals Urinary soluble VCAM-1 is a useful biomarker of disease activity and treatment response in lupus nephritis

2020 ◽  
Author(s):  
Andrese Aline Gasparin ◽  
Nicole Pamplona Bueno de Andrade ◽  
Vanessa Hax ◽  
Penélope Esther Palominos ◽  
Marina Siebert ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Disease Activity ◽  
Treatment Response ◽  
Cell Adhesion Molecule ◽  
Good Sensitivity ◽  
Class Iii ◽  
Vascular Cell Adhesion ◽  
Tubulointerstitial Injury ◽  
Cell Adhesion Molecule 1 ◽  
Over Time

Abstract Background: Vascular cell adhesion molecule-1 (VCAM-1) is involved in the progression of glomerular and tubulointerstitial injury in lupus nephritis (LN) and can be easily assessed in urine. The aim of this study was to assess urinary soluble VCAM-1 (uVCAM-1) as a biomarker of disease activity and treatment response in LN.Methods: This prospective study enrolled patients with class III, IV or V LN diagnosed within the last three years and divided them in two groups: with and without active nephritis at the inclusion. At each visit, a urine sample was collected for uVCAM-1 evaluation and the nephritis status was assessed.Results: Median uVCAM-1 level was elevated in patients with active compared to inactive LN (P<0.001). The ROC curve of uVCAM-1 demonstrated an AUC of 0.84 and a cutoff of 47.2 ng/mgCr yielded a good sensitivity (74.2%) and specificity (74.2%) for the diagnosis of active LN. A significant correlation was found between uVCAM-1 level and renal activity scores and traditional biomarkers of LN. The level of uVCAM-1 dropped in patients with active LN who went into remission (P<0.001), increased in patients who went into activity (P=0.002) and did not change in patients who remained inactive (P=0.797). The level of uVCAM-1 peaked during the flare of LN (P<0.05).Conclusion: The uVCAM-1 is a reliable biomarker that reflects renal disease activity and is useful for monitoring individual patients with lupus nephritis over time.

scholarly journals Urinary soluble VCAM-1 is a useful biomarker of disease activity and treatment response in lupus nephritis

2020 ◽  
Author(s):  
Andrese Aline Gasparin ◽  
Nicole Pamplona Bueno de Andrade ◽  
Vanessa Hax ◽  
Penélope Esther Palominos ◽  
Marina Siebert ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Disease Activity ◽  
Treatment Response ◽  
Cell Adhesion Molecule ◽  
Good Sensitivity ◽  
Class Iii ◽  
Vascular Cell Adhesion ◽  
Tubulointerstitial Injury ◽  
Cell Adhesion Molecule 1 ◽  
Over Time

Abstract Introduction: Vascular cell adhesion molecule-1 (VCAM-1) is involved in the progression of glomerular and tubulointerstitial injury in lupus nephritis (LN) and can be easily assessed in urine. The aim of this study was to assess urinary soluble VCAM-1 (uVCAM-1) as a biomarker of disease activity and treatment response in LN.Methods: This prospective study enrolled 62 patients with class III, IV or V LN diagnosed within the last three years and divided them in two groups: with and without active nephritis at the inclusion, each group with 31 patients. At each visit, a urine sample was collected for uVCAM-1 evaluation and the nephritis status was assessed.Results: Median uVCAM-1 level was elevated in patients with active compared to inactive LN (P<0.001). The ROC curve of uVCAM-1 demonstrated an AUC of 0.84 and a cutoff of 47.2 ng/mgCr yielded a good sensitivity (74.2%) and specificity (74.2%) for the diagnosis of active LN. A significant correlation was found between uVCAM-1 level and renal activity scores and traditional biomarkers of LN. The level of uVCAM-1 dropped in patients with active LN who went into remission (P<0.001), increased in patients who went into activity (P=0.002) and did not change in patients who remained inactive (P=0.797). The level of uVCAM-1 peaked during the flare of LN (P<0.05).Conclusion: The uVCAM-1 is a reliable biomarker that reflects renal disease activity and is useful for monitoring individual patients with lupus nephritis over time.

scholarly journals POS1430 EPIDEMIOLOGY OF LUPUS NEPHRITIS IN BRAZIL: FINDINGS FROM THE MACUNAÍMA STUDY - A NATIONWIDE MULTICENTRIC STUDY

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 999.1-999
Author(s):  
M. Abreu ◽  
O. Monticielo ◽  
V. Fernandes ◽  
A. Cristovão Maiorano ◽  
F. Dos Santos Beserra ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Disease Activity ◽  
Systemic Lupus ◽  
Research Support ◽  
Multicentric Study ◽  
Factors Associated ◽  
Type Iv ◽  
Damage Accrual ◽  
History Of ◽  
The Mean

Background:Lupus nephritis (LN) is one of the most serious organic manifestations of systemic lupus erythematosus (SLE). Ethnicity can contribute to disparities in the prevalence and disease activity of LN.Objectives:To assess the prevalence of LN in Brazilian patients with SLE and to determine factors associated with LN activity across the country.Methods:This cross-sectional study (GSK Study 207353) was carried out through face-to-face interviews and review of medical records (12-month study period). Adult patients with SLE (American College of Rheumatology [ACR] criteria, 1997) were included. Five SLE reference teaching centres were selected: North (NO), Northeast (NE), Midwest (CO), Southeast (SE), and South (SU). Patients with another disease whose morbidity surpassed SLE were excluded. LN was defined as reported in the medical record or history of confirmed renal biopsy; disease activity by pre-defined changes in SLE Disease Activity Index (SLEDAI) or the patient’s kidney disease during the study. Activity was assessed during (T0), 6 months before (T6), and 12 months before (T12) the interview. Systemic Lupus International Collaborating Clinics/ACR Damage Index score mapped damage accrual. Two pairings were performed, aiming to discriminate factors associated with LN and its activity, respectively. Matching technique was used to select similar individuals based on propensity scores, obtained from a logistic regression model. A bootstrapping method explored characteristic variables associated with the risk of progressing to LN.Results:Overall, 300 Brazilian patients with SLE were included in the study. Two groups were paired: LN group (N=150) and non-LN group (N = 141). The prevalence of LN in the paired sample (N=291) was 51.5%, with a disparity between centres (p<0.001; Figure 1A). Most patients were female (LN: 92.7%; non-LN: 94.3%) and the mean (standard deviation [SD]) age for the LN and non-LN groups was 39.46 (11.86) and 43.96 (12.18), respectively. History of serositis was associated with the presence of LN (42 [28.0%] vs 21 [14.9%] non-LN; p=0.010). Type IV histological class predominated in both groups, with no disparity between centres. Social disparities were noted between groups. Non-active workers prevailed among the LN group (115 [76.7%] vs 98 [69.5%] for non-LN, p=0.024).When pairing for disease activity at T12, 73 (50.3%) patients with LN (N=145) had active disease. There was regional disparity in terms of disease activity (Figure 1B), with a predominance of active LN in the NO (28 [68.3%]) and SU (16 [55.2%], p=0.026). Type IV histological class was the component most associated with active LN (active: 32 [43.8%]; non-active: 11 [15.3%], p<0.001). Variation in SLEDAI during the study period discriminated between active and non-active LN. The mean (SD) SLEDAI score at T12 was substantially higher in those with active LN compared with non-active LN (7.18 [4.83] vs 2.47 [4.63], p<0.001). As for the pattern of care, corticosteroids users prevailed in those with active LN (62 [84.9%] vs 45 [62.5%] for non-active LN, p=0.004). There was no disparity in the use of immunosuppressants, with the exception of cyclophosphamide use, noted among 16 (21.9%) patients with active LN and 6 (8.3%) patients with non-active LN (p=0.041). Psychotropic or anticonvulsant use was higher in patients with non-active LN (32 [44.4%] vs 17 [23.3%] patients with active LN, p=0.012). Consultation with a neurologist was verified in 15 (20.8%) patients with non-active LN and 6 (8.2%) with active LN (p=0.055). Hospitalisation occurred in 17 patients with non-active (23.6%) and active (23.3%) LN.Conclusion:Disparities in the prevalence of LN and its activity were evident between the regions across Brazil, highlighting differences in clinical factors, regional factors, and patterns of care.Funding:GSKFigure 1.Prevalence of A) LN among regional centres, comparing them to disease activity profile and prescriptive practice, and B) Active and non-active LN according to prescriptive practiceCQ, chloroquine; HCQ, hydroxychloroquine*At T12Acknowledgements:Medical writing assistance was provided by Helen Taylor, Fishawack Indicia Ltd., UK, part of Fishawack Health, and was funded by GSK.Disclosure of Interests:Mirhelen Abreu Grant/research support from: GSK, Amgen, Biogen, Libbs, Odirlei Monticielo Speakers bureau: GSK, AbbVie, UCB, Roche, Novartis, Consultant of: GSK, AbbVie, Janssen, Vander Fernandes Speakers bureau: Janssen, Novartis, Roche, AbbVie, Pfizer, Grant/research support from: Novartis, GSK, Pfizer, Alexandre Cristovão Maiorano: None declared, Fernando dos Santos Beserra: None declared, Flavia Lamarao Employee of: GSK, Nathalie David Shareholder of: GSK, Employee of: GSK, Bruna de Veras Employee of: GSK, Blanca Bica: None declared, Domingos Sávio Nunes de Lima Grant/research support from: GSK, Marta Maria das Chagas Medeiros: None declared

Sign in / Sign up

Export Citation Format

Share Document